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Abstract
Background and aims: Adalimumab has been shown to be effective and well tolerated in
patients with Crohn's disease. This analysis reports the results of a cohort of Japanese patients
with moderate to severe Crohn's disease who were evaluated for up to 3 years to assess the
long-term use of adalimumab.
Methods: The study consisted of a double-blind part and an open-label part. Patients were
included either in the 52-week double-blind, placebo-controlled part of the study followed by a
96-week open-label extension or in the open-label part from the beginning or in the event of a
flare. Patients were treated with adalimumab and evaluated for up to 148 weeks as 3 data
cohorts: the all-adalimumab cohort (patients receiving ≥1 injection of adalimumab), the
148-week follow-up subcohort (patients who completed 148 weeks of follow-up after the first
adalimumab dose), and the dose-escalation subcohort (patients receiving adalimumab doses
that increased to 80 mg every other week).rine; AAA, antibodies against adalimumab; ADA, adalimumab; AE, adverse event; AZA, azathioprine;
index; CR, clinical response; CR-70, CR, decrease in CDAI score of ≥70; CR-100, CR, decrease in CDAI
; IOIBD, International Organization of Inflammatory Bowel Disease; IBDQ, Inflammatory Bowel Disease
carried forward; PY, patient years; QOL, quality of life; SD, standard deviation; SF-36, Short Form 36
factor-alpha.
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1408 M. Watanabe et al.Results: In the all-adalimumab cohort (n = 79), clinical remission rates were approximately 30%
after 36 weeks of exposure to adalimumab and for the remainder of the study (35%, 33%, and
28% for weeks 48, 108, and 144, respectively). An improvement in quality of life was also
maintained over the same period. In the dose-escalation subcohort (n = 40), the clinical
remission rate was 75% (6/8) 48 weeks after dose escalation. Adalimumab was tolerated, and no
deaths were reported.
Conclusions: Adalimumab is effective for maintaining long-term clinical remission in Japanese
patients with moderate to severe Crohn's disease (NCT00445432).
© 2014 European Crohn's and Colitis Organisation. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Crohn's disease (CD) is a chronic inflammatory disorder of
the gastrointestinal tract associated with transmural inflam-
mation, which may lead to bowel damage and progressive
disability.1 Overexpression of the inflammatory cytokine
tumor necrosis factor-alpha (TNF-α) is a hallmark of CD
pathogenesis, with elevated levels of TNF-α present in the
colonic mucosa,2 blood,3 and stool.4 Therefore, recent
advances in the treatment of CD have focused on the
development of biologic agents targeted at neutralizing
TNF-α function.5 Monoclonal antibodies targeting TNF-α,
such as infliximab and adalimumab, have demonstrated
efficacy in the induction and maintenance of remission in
patients with moderate to severe CD.6,7 Infliximab was the
first TNF-α chimerical monoclonal antibody introduced for
the treatment of CD. Although infliximab is highly effective
in many patients with CD, some patients are unable to
continue on long-term infliximab maintenance therapy
because of hypersensitivity reactions or loss of response.8–10
Adalimumab (Humira®, AbbVie Inc., North Chicago, IL) is
a fully human, recombinant, subcutaneously administered
immunoglobulin G1 monoclonal antibody that binds with
high affinity and specificity to TNF-α. Adalimumab is
effective for inducing and maintaining remission in patients
with moderate to severe CD at an induction dose of 160/
80 mg (Week 0/Week 2) and at a maintenance dose of 40 mg
every other week (eow).7,11,12 In addition, adalimumab is
effective at inducing clinical remission in patients who have
lost response to or are intolerant to infliximab therapy.13 An
open-label extension trial of adalimumab in Western
patients has shown maintenance of remission through
4 years.14
Recently, the efficacy of adalimumab was demonstrated in
the treatment of CD in Japanese patients during a 4-week
induction trial followed by a 52-week maintenance trial,15 and
adalimumab was approved for the treatment of CD in Japan on
this basis. In the present maintenance trial, the long-term
safety and efficacy of adalimumab treatment for maintaining
clinical remission as well as its effect on quality of life (QOL) in
Japanese patients with moderate to severe CD were assessed.2. Materials and methods
2.1. Study design
The reported cohort is from amaintenance trial (NCT00445432)
that followed a preceding induction trial (NCT00445939) andevaluated the efficacy and safety of adalimumab in Japanese
patients with moderate to severe CD in a randomized,
double-blind, placebo-controlled design.15 The study methods
and entry criteria have been previously described.15 Briefly,
patients who were older than 15 years but younger than 75 had
been diagnosed with CD for longer than 4 months (diagnosis
was confirmed by endoscopic or radiologic evaluation), and
patients who had a CD activity index (CDAI) of 220 to 450 were
included in the induction trial and rolled over into the
maintenance trial. Patients who achieved a clinical response
(CR), defined as a decrease in CDAI of ≥70 points versus
baseline (CR-70), at the end of the 4-week induction trial
entered the randomized portion of the maintenance trial (for a
total of 52 weeks; 40 mg adalimumab or placebo eow). All the
patients who did not achieve CR-70 (nonresponders) at the end
of the 4-week induction trial entered the open-label arm of the
maintenance trial later on. In addition, patients from the
randomized, double-blind portion of the maintenance trial who
experienced a flare were also moved to the open-label arm
of the maintenance trial. Flare was defined as a recurrence
of active disease, i.e., an increase of ≥70 points in CDAI
compared with baseline in the maintenance trial and a
CDAI N220.15 Patients in the open-label arm of the mainte-
nance study were given 40 mg adalimumab eow and could
increase their dose to 80 mg eow in the event of nonresponse
or a flare. After 1 year in the maintenance study, all patients
could continue in the extension portion of the maintenance
trial and receive open-label adalimumab at a dose of 40 mg
eow or 80 mg eow for patients in the open-label arm who had
previously been dose escalated to 80 mg eow (Fig. 1).
This study was approved by the institutional review
boards of each study site and was conducted according to
the principles of the Helsinki Declaration of 1975. Patients,
or a parent or legal guardian if the patient was younger than
20 years old, provided written informed consent prior to
study participation.
2.2. Clinical assessments
The CDAI and the International Organization of Inflammatory
Bowel Disease (IOIBD) scores were assessed every 4 weeks
until Week 52x and every 12 weeks afterwards. The
Inflammatory Bowel Disease Questionnaire (IBDQ) score and
the Short Form 36 Health Survey (SF-36) summary score were
assessed at Weeks 8x, 24x, 52x, and every 24 weeks
afterwards.
Samples for measurements of adalimumab plasma levels
and antibodies against adalimumab (AAAs) were collected
every 4 weeks until Week 24x, at Weeks 36x and 52x, and
Figure 1 Study design. In this maintenance trial consisting of a 52-week double-blind portion15 and an open-label extension
portion, patients were treated with adalimumab for up to 3 years. ADA, adalimumab; eow, every other week. aOne patient was
dose-escalated to 80 mg but was in the 40-mg group at week 148.
1409every 12 weeks afterwards. The observation period for
reporting pharmacokinetic data was from Week 52x to
148x. The methodologies for analyzing the samples for
adalimumab and AAA measurement have been previously
published.15 Safety was assessed by evaluating reported and
observed adverse events (AEs), vital sign measurements, and
clinical laboratory tests (i.e., chemistry, hematology,
urinalysis).
2.3. Patient cohorts
Three cohorts of patients were assessed in this study: the
all-adalimumab cohort, which included all patients who
received at least 1 injection of adalimumab in the
maintenance trial, the dose-escalation subcohort, which
included patients whose adalimumab doses were increased
to 80 mg eow, and the 148-week follow-up subcohort, a
group of patients who completed 148 weeks of follow-up
after the first dose of adalimumab, some of whom continued
treatment beyond this follow-up time point (Fig. 1).
Adalimumab treatment in this study was designed to be
continuous.
2.4. Endpoints
For the all-adalimumab cohort and 148-week follow-up
subcohort, the proportion of patients achieving clinical
remission (CDAI b150) was assessed as well as the proportion
of patients achieving CR-70 and CR-100 (defined as a decrease
in CDAI score of at least 100 points compared with baseline).
Other endpoints included mean change from baseline in CDAI
and mean change from baseline in IOIBD, IBDQ, and SF-36
summary scores. The primary observation period for the
reporting of efficacy, safety, and pharmacokinetic data was
148 weeks after initiation of first dose of adalimumab in this
maintenance study. For the dose-escalation subcohort, the
proportion of patients achieving clinical remission (CDAI
b150) was evaluated for 48 weeks after dose escalation.2.5. Statistical analyses
Baseline and demographic characteristics, efficacy analyses,
safety data, and pharmacokinetics were summarized using
descriptive statistics. The baseline values for demographic
characteristics and safety and efficacy analyses were desig-
nated as the values immediately before or during the last
evaluation before the first dose of the study drug in the
preceding induction trial. Efficacy, safety, and pharmacoki-
netic measurements were obtained throughout the study.
Efficacy was assessed from the initiation of the first dose of
adalimumab in the maintenance part of the trial. Some
efficacy endpoints were also evaluated using Kaplan–Meier
survival time analysis. Missing data on clinical remission rates
endpoints were imputed by last observation carried forward
(LOCF; missing values were replaced by the last observed
value and reported at Week 144 for the primary observation),
nonresponder imputation, or as-observed method (reported
at Week 148 for the primary observation). All other efficacy
and QOL endpoints were assessed by as-observed analysis.
Serum adalimumab and AAA concentrations were summarized
by patient cohorts at each time point using descriptive
statistics. The differing lengths of the induction trial among
patients entering the maintenance trial were accommodated
by designating the week of entering into the maintenance
trial Week “0x,” and including an “x” in the numbering on the
following weeks. The week “x” designation further differen-
tiates between time on the maintenance trial versus time on
adalimumab treatment in the maintenance trial, which is
used for several of the analyses.
3. Results
3.1. Patient disposition
Of the 50 patients who were considered to be responders in
the 4-week induction trial and entered the double-blind,
randomized maintenance trial, 25 patients each were
1410 M. Watanabe et al.randomized to adalimumab and placebo treatment (Fig. 2).
Of the 25 patients randomized to placebo, 3 (12%) patients
discontinued the study and are not considered in the present
analysis, 20 (80%) patients moved to the open-label arm of
adalimumab treatment, and 2 (8%) patients completed the
blinded portion of the study until Week 52x. These 2 patients
were then moved to the open-label extension portion of the
maintenance trial. Of the 25 patients randomized to
adalimumab, 1 patient discontinued the study, 14 patients
moved to the open-label arm of adalimumab treatment, and
10 patients completed the blinded portion of the study until
Week 52x. Thirty-two of the 33 patients who were
nonresponders at Week 4 of the induction trial subsequently
entered the open-label arm of the maintenance trial at
Week 0x.
In total, 79 patients received at least 1 injection of
adalimumab in this study and constitute the all-adalimumab
cohort. Of these, efficacy analyses are available for 37
patients who completed 148 weeks of follow-up. These 37
patients compose the 148-week subcohort and have been
included in the LOCF analysis; however, 1 patient dis-
continued before the final efficacy visit, and therefore 36
patients have been included in the as-observed analysis at
Week 148 (Fig. 1). Eight of these 37 patients were randomized
to placebo and 16 to adalimumab 40 mg eow, and 13 entered
the open-label adalimumab arm at Week 0x of the mainte-
nance trial. Forty patients in the all-adalimumab cohort
entered the dose-escalation subcohort, and 16 of these
patients completed the study. Fig. 2 summarizes the
disposition of patients through 148 weeks of follow-up, and
patient discontinuations are summarized in Supplemental
Table 1.3.2. Demographics and baseline characteristics
The mean age of patients in the all-adalimumab cohort was
30.9 years, and 59.5% of the patients were male (Table 1).Figure 2 Patient disposition through up to 3 yeaThe mean baseline CDAI total score was 301; 57% of the
patients had a CDAI score of less than 300 and 43% of the
patients had a CDAI score of 300 or greater. The mean IBDQ
score, which was an indicator for QOL, was 146.7, and the
mean SF-36 scores were 43.8 and 39.3 on the physical and
mental components, respectively. For IBDQ, a score above
170 is generally considered to be in IBDQ remission. For
SF-36, a score of 50 is considered as a mean for the general
population. Corticosteroids were used as a previous medi-
cation for CD by 11.4% of the patients in the all-adalimumab
cohort, while 19% of patients in this cohort previously used
infliximab for the treatment of CD. Immunomodulators and
corticosteroids were concomitantly used in 25.3% and 20.3%
of the patients in the all-adalimumab cohort, respectively.
The demographic and baseline patient characteristics of the
dose-escalation and the 148-week follow-up subcohorts
were similar to those in the all-adalimumab cohort
(Table 1).3.3. Efficacy
In the all-adalimumab cohort, clinical remission rates (LOCF
analysis) were approximately 30% after Week 36 and through
Week 144 of adalimumab treatment (Fig. 3), and the clinical
remission rate at Week 144 was 28.2% (22/78). Remission
rates were slightly lower when analyzed using a nonrespond-
er imputation (i.e., 25.3% of the patients at Week 36 and
26.6% at Week 148). Clinical remission rates were higher
(Fig. 4) and median time to remission was shorter in patients
treated with concomitant azathioprine or 6-mercaptopurine
compared with patients not treated with azathioprine or
6-mercaptopurine at baseline (median, 99 vs 252 days,
respectively; hazard ratio, 0.65; 95% confidence interval,
0.35–1.89; P = 0.16). Clinical remission rates for patients
treated with or without concomitant azathioprine or
6-mercaptopurine throughout the study followed a similar
trend and are summarized in Supplemental Table 2.rs. ADA, adalimumab; eow, every other week.
Table 1 Patient demographics and baseline characteristics. a
Characteristic All-adalimumab cohort
(n = 79)
148-week follow-up subcohort
(n = 37)
Dose-escalation subcohort
(n = 40)
Sex, n (%)
Male 47 (59.5) 25 (67.6) 24 (60.0)
Female 32 (40.5) 12 (32.4) 16 (40.0)
Age, mean ± SD, y 30.9 ± 8.0 30.4 ± 8.5 30.2 ± 8.2
Age, n (%)
b30 y 35 (44.3) 21 (56.8) 18 (45.0)
30–39 y 30 (38.0) 9 (24.3) 14 (35.0)
40–64 y 14 (17.7) 7 (18.9) 8 (20.0)
Weight, kg
Mean ± SD 56.4 ± 9.7 57.2 ± 10.8 57.5 ± 10.4
Range 37.0–81.4 38.7–81.4 41.3–81.4
Tobacco, nonsmoker, n (%) 49 (62.0) 18 (48.6) 24 (60.0)
Alcohol, nondrinker, n (%) 51 (64.6) 22 (59.5) 21 (52.5)
Duration of CD, y
Mean ± SD 9.5 ± 6.3 7.9 ± 4.7 9.6 ± 7.2
Range 0.3–27.4 1.1–21.3 0.3–27.4
CDAI score
Mean ± SD 300.9 ± 62.8 298.6 ± 61.8 297.9 ± 58.4
Range 221–448 221–448 222–448
CDAI score, n (%)
b300 45 (57.0) 21 (56.8) 23 (57.5)
≥300 34 (43.0) 16 (43.2) 17 (42.5)
IOIBD score
Mean ± SD 3.3 ± 1.4 3.2 ± 1.1 3.5 ± 1.3
Range 1–7 1–6 1–7
IBDQ score, mean ± SD 146.7 ± 25.4 147.1 ± 25.6 150.3 ± 24.8
SF-36 summary score, mean ± SD
Physical component 43.8 ± 6.6 44.2 ± 7.0 43.5 ± 5.5
Mental component 39.3 ± 10.6 38.4 ± 10.8 39.9 ± 8.8
C-reactive protein, n (%)
≥1 mg/dL 53 (67.1) 24 (64.9) 28 (70.0)
b1 mg/dL 26 (32.9) 13 (35.1) 12 (30.0)
Median, mg/dL 1.58 1.24 1.74
Prior CD medication, n (%)
Infliximab 15 (19.0) 9 (24.3) 25 (62.5)
Prednisolone 9 (11.4) 6 (16.2) 6 (15.0)
Concomitant CD medication, n (%)
Azathioprine 20 (25.3) 9 (24.3) 6 (15.0)
Prednisolone 16 (20.3) 9 (24.3) 9 (22.5)
CD, Crohn's disease; CDAI, Crohn's disease activity index; IBDQ, Inflammatory Bowel Disease Questionnaire; IOIBD, International
Organization of Inflammatory Bowel Disease; ND, not determined; SF-36, Short Form 36 Health Survey; SD, standard deviation.
a Baseline is the last measurement time point before the first dose of study medication in the induction trial.
1411However, clinical remission rates were not affected by
baseline corticosteroid use. Using an as-observed analysis,
the clinical remission rate after the first administration of
adalimumab was 41.7% (20/48 patients) at Week 52, 59.1%
(26/44) at Week 100, and 58.3% (21/36) at Week 148. Similar
results were observed for the 37 patients who completed
148 weeks of adalimumab therapy. The clinical remission
rates in this subcohort (as-observed analysis) were 62.2%
(23/37 patients) at Week 100 and 58.3% (21/36) at Week
148. Based on as-observed analysis, clinical remission
rates in patients in the all-adalimumab cohort who were
responders at Week 4 of the induction period and wererandomized to double-blind adalimumab treatment were
80.0% (8/10), 77.8% (7/9), and 71.4% (5/7) for Weeks 48,
100, and 148, respectively. Similar to the clinical remission
rates, CR-70 and CR-100 remained at greater than 60% and
55%, respectively, after Week 36 through Week 148 of
adalimumab treatment in patients in the all-adalimumab
cohort and in the 148-week follow-up subcohort. The median
survival time for CR-70 in the all-adalimumab cohort was
45 weeks (95% confidence interval, 13–158; Fig. 5). The
analysis of the mean changes from baseline in CDAI in the
all-adalimumab cohort indicated a sustained reduction in
CDAI (≥100) throughout the 148 weeks of adalimumab
Figure 5 Kaplan–Meier curves for maintenance of long-term
clinical response (CR-70). Long-term clinical response was
maintained in some patients for approximately 3 years in the
all-adalimumab cohort. The median survival time was 45 weeks
(95% confidence interval, 13–158). CR-70, clinical response,
decrease in Crohn's disease activity index score of ≥70.
Figure 3 Clinical remission rate in the all-adalimumab
cohort: LOCF analysis. The clinical remission rate remained
around 30% after Week 36 throughout 148 weeks of adalimumab
treatment. Week 0 is the time of the first dose of adalimumab.
LOCF, last observation carried forward.
1412 M. Watanabe et al.treatment (Table 2). Similarly, the mean changes in IOIBD
score from baseline in the all-adalimumab cohort (Fig. 6)
and 148-week follow-up subcohort remained reduced by 1 or
more at all time points.
In patients in the dose-escalation subcohort (n = 40), the
clinical remission rate was 0 at the dose-escalation visit,
which subsequently increased after the adalimumab dose
increase from 40 mg eow to 80 mg eow and was 75% (6 of 8
patients remaining in the subcohort) at 48 weeks after dose
escalation (about 1 year; as-observed analysis). CR-70 and
CR-100 were 7.5% (3/40) and 2.5% (1/40), respectively, at
the dose-escalation visit and, similar to the CR rate,
remained high 48 weeks after dose escalation (100% [8/8]
and 87.5% [7/8] for CR-70 and CR-100, respectively). Clinical
remission rates and CR-70 and CR-100 values for the
dose-escalation cohort (as-observed analysis) for all visits
from dose-escalation through the primary observation at
Week 48 after dose-escalation are summarized in Supple-
mental Table 3. Additionally, the mean change from
baseline in observed CDAI scores was −191.6 in theFigure 4 Clinical remission rate with and without concomi-
tant use of AZA/6-MP or prednisolone in the all-adalimumab
cohort: LOCF analysis. Clinical remission rates were greater in
patients treated with concomitant AZA/6-MP compared with
patients not treated with AZA/6-MP at baseline. However,
clinical remission rates were not affected by baseline cortico-
steroid use. AZA/6-MP, azathioprine/6-mercaptopurine; LOCF,
last observation carried forward.dose-escalation subcohort at 48 weeks after dose escalation
(n = 8).
3.4. Health-related QOL
The mean changes from baseline in IBDQ score in the
all-adalimumab cohort increased and remained at 16 or
greater after the first administration of adalimumab
(Table 3). A change of 16 points is considered clinically
meaningful. At most visits, the change scores were well
above the minimal clinically important difference of 16
points. The mean IBDQ score at Week 148 was 174.4, which is
above the cut for remission. The percentage of patients with
IBDQ scores ≥170 at Week 148 was 56.8% (21/37). Similarly,Table 2 Mean CDAI and change from baseline in CDAI after
first administration of adalimumab in the all-adalimumab
cohort. a
Week Patients, n CDAI,
mean
Change from baseline,
mean ± SD
0 78 222.8 −76.6 ± 87.9
12 73 197.4 −99.4 ± 90.0
24 63 179.0 −121.9 ± 89.9
36 56 187.6 −110.6 ± 81.3
48 47 159.2 −136.5 ± 85.5
64 51 175.5 −124.8 ± 96.1
76 50 160.8 −139.8 ± 99.4
88 46 150.6 −146.1 ± 100.1
100 44 153.9 −141.9 ± 109.7
112 41 135.7 −158.3 ± 94.7
124 38 142.6 −153.8 ± 97.5
136 39 153.5 −143.2 ± 104.4
148 36 156.9 −143.0 ± 102.5
CDAI, Crohn's disease activity index; SD, standard deviation.
a Baseline is the last measurement time point before the first
dose of study medication in the induction trial.
Figure 7 Mean serum adalimumab concentrations versus time
after week 52x. Serum adalimumab concentrations remained
constant after Week 52x in both patients who remained on
40 mg eow adalimumab treatment and those who dose escalat-
ed to 80 mg eow. The error bars denote standard deviation.
eow, every other week.
Figure 6 Mean changes in IOIBD score from baseline in the
all-adalimumab cohort: as-observed analysis. Mean changes in
IOIBD score from baseline remained reduced by at least 1 after
the first administration of adalimumab. IOIBD, International
Organization of Inflammatory Bowel Disease.
1413the mean change from baseline in SF-36 scores (the physical
and mental components) increased and remained at 3 or
greater during most of the period after the first administra-
tion of adalimumab. A change of 3 points in SF-36 is
considered clinically meaningful. At Week 148, the change
in mental component summary score was 2 times that
of clinically meaningful difference of 3 points. Similar
results were observed for the 148-week follow-up
subcohort. In summary, the increases in mean IBDQ and
SF-36 scores observed in this study are considered clinically
meaningful.
3.5. Pharmacokinetics
After Week 52x, the mean adalimumab trough concentrations
in those who continued the open-label period were compa-
rable between the patients receiving 40 mg eow and those
who were dose escalated to 80 mg eow (Fig. 7). The mean
adalimumab trough concentrations remained relatively con-
stant from Week 64x to 148x (7–9 μg/mL) for the 27 patients
who remained on 40 mg eow. The mean adalimumab troughTable 3 Mean change from baseline in IBDQ and SF-36 scores aft
cohort. a
Week Patients, n IBDQ score SF-36
Mean Change from baseline,
mean ± SD
Mean
0 64 166.3 20.6 ± 23.8 48.1
8 74 162.5 16.1 ± 32.1 46.2
24 68 165.5 17.0 ± 33.2 47.4
52 55 167.3 21.2 ± 29.8 48.6
76 52 172.8 25.9 ± 26.7 49.0
100 45 174.0 27.9 ± 31.4 50.5
124 40 172.5 24.3 ± 33.8 49.9
148 37 174.4 27.2 ± 31.2 49.6
IBDQ, Inflammatory Bowel Disease Questionnaire; SF-36, Short Form 36
a Baseline is the last measurement time point before the first dose oconcentrations for the 27 patients who dose escalated to
80 mg eow remained between 9 to 11 μg/mL from Week 64x
to 148x. Five patients developed AAAs before Week 52x, and
only 2 of these continued the study after Week 52x. No
patients developed AAAs after Week 52x.3.6. Safety
A total of 79 patients received at least 1 injection of
adalimumab (constituting the all-adalimumab cohort),
representing 155.3 patient-years (PY) of adalimumab expo-
sure (Table 4). Adverse events occurred in all patients within
this cohort (n = 79), and the number of AEs per 100 PY was
743.1. The incidence of AEs that were possibly drug related
was 59.5% of the total number of AEs. The incidence of
serious AEs was 62.0% (56.7 serious AEs/100 PY); the serious
AEs were predominantly related to underlying CD. A total of
35.4% of patients discontinued because of an AE. Adverseer first administration of adalimumab in the all-adalimumab
physical component SF-36 mental component
Change from baseline,
mean ± SD
Mean Change from baseline,
mean ± SD
4.2 ± 5.1 42.5 3.9 ± 9.6
2.9 ± 8.3 41.8 2.6 ± 11.2
3.4 ± 8.8 44.1 4.4 ± 11.1
4.3 ± 7.6 42.9 4.7 ± 12.0
4.5 ± 9.2 45.0 6.8 ± 11.1
6.4 ± 7.4 43.7 5.4 ± 10.5
5.6 ± 8.2 43.6 5.1 ± 10.5
5.4 ± 7.2 44.8 6.4 ± 11.2
Health Survey; SD, standard deviation.
f study medication in the induction trial.
Table 4 Summary of AEs After First Administration of Adalimumab to 148 Weeks of Adalimumab Exposure in the All-Adalimumab
Cohort.
Type of AE Patients, n (%)
(N = 79)
Number of AEs
(AEs/100 PY) a
PY = 155.3
Any AE 79 (100) 1154 (743.1)
Possibly drug related 47 (59.5) 127 (81.8)
Serious AE 49 (62.0) 88 (56.7)
Leading to early discontinuation 28 (35.4) 29 (18.7)
AE of interest
Infection 68 (86.1) 337 (217.0)
Serious infection 9 (11.4) 11 (7.1)
Malignancy 0 0
Injection-site reaction 6 (7.6) 6 (3.9)
Opportunistic infection b 1 (1.3) 1 (0.6)
Tuberculosis 0 0
Congestive heart failure 0 0
Demyelinating disease 0 0
Hepatic event 21 (26.6) 36 (23.2)
Allergic reaction 1 (1.3) 1 (0.6)
Lupus-like syndrome 0 0
Blood disorder 2 (2.5) 2 (1.3)
AE, adverse event; PY, patient-years.
a PY = 155.3.
b Excluding tuberculosis.
1414 M. Watanabe et al.events of interest with anti-TNF agents include serious
infections, malignancies, opportunistic infections (excluding
tuberculosis), and demyelinating disease. In the all-
adalimumab cohort, 9 (11.4%) patients developed serious
infections during the study, 3 of which were possibly related
to the study drug. These infections included abdominal
abscess in 2 patients and pneumonia in 1 patient. No deaths,
lupus-like syndromes, demyelinating disease, congestive
heart failure, tuberculosis, or malignancy cases were re-
ported in this patient cohort. The incidence of injection-site
reaction was low (7.6%) and mild in severity. The incidence
of hepatic events, which were not study related, was 26.6%.
The hepatic events that developed in more than 5% of
patients were an increase in gamma-glutamyltransferase
(7.6%) and abnormal hepatic function (5.1%) (measured as an
increase in aspartate aminotransferase b alanine amino-
transferase and gamma-glutamyltransferase). Of the 37
patients in the 148-week follow-up subcohort, a serious AE
occurred in 18 (48.6%) patients, 3 (8.1%) patients developed
a serious infectious AE, and 3 (8.1%) patients discontinued
study drug due to an AE. The incidence of AEs was 77.5%
(31/40) before the dose escalation and 95.0% (38/40) after
the dose escalation. The frequency of AEs was 901.1 AEs/
100 PY before dose escalation and 764.8 AEs/100 PY after
dose escalation (summarized in Supplemental Table 4).
However, the frequency of serious AEs was higher after the
dose escalation (34.2 and 63.2 serious AEs/100 PY, respec-
tively, before and after dose escalation). At the time of dose
escalation, the symptoms of CD in these patients may have
been worse than before dose escalation, as some of the
serious AEs observed after dose escalation included aggra-
vation of CD (15 serious AEs in 11 patients), ileus (3 seriousAEs in 3 patients), and peritonitis (2 serious AEs in 2
patients), most of which were associated with underlying
diseases.4. Discussion
The purpose of this study was to evaluate the efficacy and
safety of adalimumab as a means of maintaining clinical
remission in patients with moderate or severe CD who
responded to induction therapy with adalimumab during the
preceding study15 and the long-term continued adalimumab
treatment in patients with CD who did not respond to
induction therapy. In addition, the value of the escalated
dose of adalimumab to 80 mg eow in patients who had a
relapse of CD was also evaluated.
Because of the low prevalence of CD in Japan,16 these
trials were designed with a small sample size. However, the
long-term efficacy and safety of adalimumab in Japanese
patients with CD were expected to follow a similar trend as
previously shown in Western patients.14,17 This study
enrolled 83 of the 84 patients who completed the preceding
induction study15; of these, 79 patients received at least 1
injection of adalimumab and constitute the all-adalimumab
cohort. The results of this trial demonstrate that the long-
term administration of adalimumab as maintenance therapy
in Japanese patients with moderate to severe CD was well
tolerated and effective. The clinical remission rate and
change in CDAI from baseline after open-label adalimumab
treatment remained high at each visit, indicating that the
disease activity remained reduced over a long period with
this therapy. Furthermore, the reduction in IOIBD score from
1415baseline was also maintained during this period. Despite the
limited number of patients enrolled in this study, the results
of this long-term study are consistent with the long-term
adalimumab data from the ADHERE trial with Western
patients.14,17
Of the 79 patients included in the all-adalimumab
cohort, the dose was increased from 40 mg to 80 mg due
to CD relapse or lack of efficacy for 40 patients. About 75%
(6/8) of these patients were in clinical remission at
48 weeks after the dose escalation, which is consistent
with data from a Western study.18 These results demon-
strate that adequate responses can be obtained by
increasing the dosage of adalimumab from 40 mg eow to
80 mg eow in patients who experience a relapse of CD or
lack of drug efficacy. The results from the all-adalimumab
cohort and subcohort who completed 148 weeks of
follow-up also suggest that these responses can be
maintained for a long period in some patients. These
results are consistent with what was observed in the CHARM
trial with Western patients.7
Adalimumab therapy resulted in QOL improvement, and
long-term treatment with adalimumab maintained this
improvement based on IBDQ and SF-36 scores. These results
are consistent with QOL improvements observed in the
CHARM trial in Western patients with CD.7 Quality of life is
particularly important because patients with active CD are
known to show reduced QOL scores over time.19 Therefore,
it is clinically important to reduce the activity level of the
disease as well as to maintain improved QOL scores when
managing CD.
Serum adalimumab levels remained relatively constant
after Week 52x, as was observed in the 1-year study15 and
other studies of adalimumab in Western patients with
CD.11,12 Although the rate of immunogenicity through
1 year of adalimumab treatment was slightly higher than
the CLASSIC II trial (6.1% vs 2.6%), there were no new cases
in the 2-year period after Week 52x in this study.12,15
The adverse event profiles for adalimumab therapy in this
study were similar to those reported in other clinical trials of
adalimumab in Western patients with CD,14,17 and no deaths
were reported. Adverse events occurred in all patients in the
all-adalimumab cohort; the number of AEs per 100 PY was
743.1, which is similar to the 713.0 AEs per 100 PY observed in
Western patients with CD in a 2-year long-term study.12 In
addition, patients with CD experience a substantial rate of AEs
as evidenced by the AE rates observed for placebo recipients in
controlled trials of adalimumab.11,13 The incidence of serious
AEs was 62.0% in this study; however, most of the events were
associated with underlying CD. In the patients in the dose-
escalation subcohort, the incidence of AEs was higher after
dose escalation than before dose escalation. Because CD
symptoms tended to be aggravated (relapse of the disease or
lack of efficacy) at the time of the dose escalation, it is likely
that the incidence of AEs associated with the underlying CD
increased after the dose escalation.
Overall, this long-term study demonstrates that
adalimumab therapy can sustain remission and improve-
ments in QOL scores for at least 3 years in Japanese patients
with moderate to severe CD. The results also demonstrated
the usefulness of increasing the adalimumab dosage to
80 mg eow when treating disease relapse in patients who
received adalimumab 40 mg eow.Conflicts of interest
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